13. - 17.03.2016 - SOT 55th Annual Meeting and ToxExpo

  SOT web logo

Multi-donor Microtissues | Exhibitor-hosted Sessions | Posters | Beers & Spheres Social

Join InSphero at the 55th Annual Meeting of the Society of Toxicology to learn more about how 3D InSight™ Microtissues & Services can help you evaluate, adopt, and integrate advanced 3D models into your safety testing workflow. We’ve got big news to share this year, as we present results from an in-depth characterization of the DILI-predicting capabilities of our 3D liver microtissues, and introduce our newest assay-ready microtissue model: 3D InSight™ Multi-donor Human Liver Microtissues. These multi-donor microtissues pack macro-power, while representing a more diverse genomic background in which to test for drug-induced liver injury. With convenient kit and service options, we’ve made integrating them as easy as 1-2-3, so you can be up and running before summer arrives.

Join us at one of our 11 scientific sessions, socialize at our Monday Beers and Spheres event, or visit us at booth 1844/1845 to browse our in-booth poster hall while enjoying an invigorating beverage.


Introducing the ideal model for predicting DILI


3D InSight™ Multi-donor Human Liver Microtissues offer the same structural and functional robustness of our single-donor 3D InSight™ Human Liver Microtissues, while mitigating potentially confounding responses resulting from single-donor CYP polymorphisms. By pooling hepatocytes from 10 donors (5 male, 5 female), multi-donor microtissues more closely approximate the average human response, and extend donor lot availability to ensure a long-term supply of donor material. Available as co-culture with Kupffer cells, multi-donor microtissues are ideal for DILI testing and mechanistic toxicity studies.


3 “Big Easy” Steps to 3D Integration

The world’s leading pharmaceutical companies have integrated InSphero 3D InSight™ Liver Microtissues into their DILI testing, now we’ve made it simple for you to do the same.

With our 3D InSight™ DILI Evaluation Service, you evaluate multi-donor microtissues by letting our experts do all the work. We test 6 of your compounds and determine an IC50 using a 14 day, repeat-dosing protocol with ATP endpoint. You get the results to compare to our reference compound data in just 3 weeks.

Our 3D InSight™ DILI Evaluation Kit provides enough multi-donor microtissues, optimized media, 6 reference compounds, ATP assay reagents, and a detailed protocol to simplify in-house adoption of InSphero microtissues. As you implement the 3D protocol, you’ll also be validating the results of your evaluation project. You get the full support of our 3D experts, and in about 3 weeks you'll be ready to integrate.

Review our regular microtissue production schedule, and order plates of 3D InSight™ Microtissues as you need them. Enjoy the assay-ready convenience of standardized 3D liver models and optimized media delivered to your lab, and the satisfaction of knowing you’re using the most biologically relevant in vitro DILI testing model available. Focus on the results, and leave the production and QC to InSphero.


Your 3D InSight™ Conference Planner

Conference Date
13. - 17. March, 2016

New Orleans Morial Convention Center


Download the SOT Meeting App
View the SOT Online Meeting Planner

  Exhibitor-hosted Sessions

Monday, 4:30 - 5:30 PM, Room 205
Use of 3D InSightTM Human Liver Microtissues as a Tool for Prediction of Drug-induced Liver Injury
Prediction of DILI is an important task in drug developmment. InSphero will present the results from recent evaluation studies by the pharmaceutical industry using 3D InSight Human Liver Microtissues for prediction of DILI, performed with more than 100 clinically known test compounds.

Monday, 4:30 - 5:30 PM, Room 211
Functional Assays for Assessing Mitochondrial Toxicants and Other Energy Metabolism Disruptors in Live Cells
presented by Seahorse Bioscience, a part of Agilent Technologies, featuring InSphero Human Liver Microtissues

Tuesday, 10:30 - 11:30 AM, Room 213
Combining Real-Time Measurement of Cell Viability and Extraction of RNA from the same 3D Spheroids
presented by Promega Corporation

Tuesday, 4:30 - 5:30 PM, Room 213
Evolution of the Spheroid: Advanced 3D Microtissue Models as a Versatile Tool for more Physiologically Relevant Efficacy and Safety Assessment

3D Microtissues reflect organ physiology more closely than conventional 2D cultures, but are still amenable to automation. Here the recent developments in 3D microtissue technology are presented which allow for high throughput efficacy and safety testing. In addition, incorporation of spheroids into microphysiological systems will be discussed


Monday, March 14, 1:15 - 4:30 PM
1669/P554: Utility of 3D Human Liver Microtissues for Prediction of Compounds that cause Drug-induced Liver Injury in Humans
with AstraZeneca and Genentech

Tuesday, March 15. 1:15 - 4:30 PM
2173/P150: 3D HepaRG Microtissues for Improved ADME/Tox Predictions
with Biopredic

Tuesday, March 15, 1:15 - 5:30 PM
2000/P404: In-depth Characterization of 3D Human Liver Microtissues by Transcriptomic, Proteomic and Functional Analysis

with Karolinska Institute

Thursday, March 17, 9:30 AM - 12:45 PM
3460/9150: Pro-drug Activation and Detoxification in a Dynamic Microfluidic System
with ETH Zurich

Thursday, March 17, 9:30 AM - 12:45 PM
3705/P397: Evaluation Of A Novel Standardized In Vitro Human Islet Model System For Assessment Of Drug-related Pancreatic β Cell Functional Perturbation
with Amgen

Thursday, March 17, 09:30 AM - 12:45 PM
3553/P245: Combining a Real-time In Vitro Cell Viability Assay and RNA Extraction From the Same 3D Spheroids
presented by Promega

Thursday, March 17, 9:30 AM - 12:45 PM
3911/P603: Development of a 3D Dog Liver Microtissue Model
with Pfizer


Monday Night Beers & Spheres Social








Company video